FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of February 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [ X ] Form 40 - F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [ X ]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on February 9, 2000, titled:
"Vasogen Announces $14.4 Million Financing"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/Christopher Waddick
----------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: February 9, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive, Suite 10 Trevor Burns
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel (905) 569-2265 fax (905) 569-9231 tel (905) 569-9065
http://www.vasogen.com e-mail [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen Announces $14.4 Million Financing
Toronto, Ontario (February 9, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW)
announced today that it has received commitments, primarily from senior U.S.
institutional investors, to purchase directly 1,600,000 special warrants at
$9.00 (Cdn.) per special warrant. The net proceeds of the offering, after
deducting expenses of the issue, will be approximately $14.2 million (Cdn.).
Proceeds of the financing will be used to advance the commercial development of
Vasogen's proprietary immune modulation therapies, accelerate fundamental
research into new areas of clinical application, pursue strategic business
partnerships, and as additional working capital. Closing is anticipated, subject
to regulatory approval, on or about February 22nd, 2000.
The Company's projected cash position as at February 29, 2000, including
proceeds of this financing, is anticipated to be $23 million (Cdn.).
Each special warrant is convertible into one common share of Vasogen Inc. for no
additional consideration. Following closing, the Company will file a preliminary
prospectus in Ontario to qualify the common shares to be issued on the exercise
of the special warrants.
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective
treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
